Roivant Sciences (ROIV) PT Raised to $18 at H.C. Wainwright, 'brepocitinib has blockbuster potential'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts ROIV Hot Sheet
Price: $37.91 +5.19%
Rating Summary:
13 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
13 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
(Updated - April 3, 2024 6:44 AM EDT)
H.C. Wainwright analyst Douglas Tsao raised the price target on Roivant Sciences (NASDAQ: ROIV) to $18.00 (from $17.00) while maintaining a Buy rating.
The analyst commented: 'Across the NIU and dermatomyositis, we believe brepocitinib has blockbuster potential. We raise our price target to $18 from $17 with this pipeline success as well as the company's announcement that it is buying back the shares held by Sumitomo Pharma for $648M, reducing the share count by ~9%.'
You May Also Be Interested In
- Flutter Entertainment (FLUT) PT Lowered to $160 at Jefferies
- SGHC Limited (SGHC) PT Lowered to $16 at StoneX
- Bruker (BRKR) PT Raised to $70 at Jefferies
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
H.C. WainwrightSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
